RxDoctor Payments Data

Eddrea Cade

Family · Montgomery, ALNPI 1811474190

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,148 and has fallen 88.0% since, to $257 in 2025. Among family clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,543in general payments, 2019–2025

Across 319 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$438
  • AbbVie$398
  • Amgen$288
  • Arbor Pharmaceuticals, Inc.$283
  • Amarin Pharma, Inc.$250
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,543 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama →

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$20,876
Gabapentin38$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$438$20,87614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.

Other family in Montgomery

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →